Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

bimagrumab

A human monoclonal antibody directed against type II activin receptors (ActRII; ActR2), with potential muscle-sparing and anti-cachectic activities… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
BACKGROUND Inclusion body myositis is an idiopathic inflammatory myopathy and the most common myopathy affecting people older… Expand
Is this relevant?
2018
2018
AIM To test the hypothesis that an improving body composition in insulin-resistant individuals could enhance insulin sensitivity… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2017
Highly Cited
2017
OBJECTIVES To assess the effects of bimagrumab on skeletal muscle mass and function in older adults with sarcopenia and mobility… Expand
  • figure 1
  • table 1
  • table 2
Is this relevant?
2017
2017
Abstract Background Patients experiencing disuse atrophy report acute loss of skeletal muscle mass which subsequently leads to… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
2017
2017
Significance We recently reported that activin type II receptors (ActRIIs) blockade using bimagrumab could positively impact… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
Objective: To examine efficacy and safety of bimagrumab (BYM338)in patients with sporadic inclusion body myositis (sIBM) measured… Expand
Is this relevant?
Review
2016
Review
2016
ABSTRACT Introduction: Cachexia and sarcopenia are conditions phenotypically characterized by muscle loss and represent a factor… Expand
Is this relevant?
2016
2016
Bimagrumab (BYM338) is a novel fully human monoclonal antibody that exerts strong promyogenic effects on skeletal muscle by… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Objective: To study activin signaling and its blockade in sporadic inclusion body myositis (sIBM) through translational studies… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
The myostatin/activin type II receptor (ActRII) pathway has been identified to be critical in regulating skeletal muscle size… Expand
Is this relevant?